NewsBenzingaRein Therapeutics Reports Preliminary 12-Week Blinded Phase 2 RENEW Data For LTI-03 In IPF Patients; Study Achieves 75% Enrollment, With 90 Patients Randomized To Date; On Track To Report Topline Data In 2027 Rein Therapeutics Reports Preliminary 12-Week Blinded Phase 2 RENEW Data For LTI-03 In IPF Patients; Study Achieves 75% Enrollment, With 90 Patients Randomized To Date; On Track To Report Topline Data In 2027 Benzinga 2026.11.16 12:32 (GMT+0) Open on Benzinga Other news TD Cowen Maintains Buy on Netskope, Raises Price Target to $25 TD Cowen Maintains Buy on Navan, Raises Price Target to $32 TD Cowen Maintains Hold on NextDecade, Raises Price Target to $7.5 Corvex Secures $103M Nvidia Blackwell AI Computing Deal TD Cowen Maintains Buy on Milestone Pharmaceuticals, Lowers Price Target to $5 Helus Pharma Touts Positive Data for Depression Drug